Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cel-Sci Corp (CVM)

Cel-Sci Corp (CVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 51,944
  • Shares Outstanding, K 8,016
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,920 K
  • EBIT $ -25 M
  • EBITDA $ -21 M
  • 60-Month Beta 0.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.95

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 85.64%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Expected Move (DTE 34) 2.79 (46.31%)
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A
  • Expected Range 3.23 to 8.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.70
  • Growth Rate Est. (year over year) +37,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.56 +14.39%
on 12/03/25
7.80 -18.46%
on 11/28/25
-0.38 (-5.64%)
since 11/12/25
3-Month
5.56 +14.39%
on 12/03/25
10.83 -41.27%
on 10/03/25
-3.89 (-37.95%)
since 09/12/25
52-Week
1.98 +221.21%
on 06/02/25
32.70 -80.55%
on 12/19/24
-15.76 (-71.24%)
since 12/12/24

Most Recent Stories

More News
CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, previously announced that Geert Kersten, Chief Executive...

CVM : 6.36 (-1.85%)
CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

Vienna, Virginia--(Newsfile Corp. - October 10, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced that Geert Kersten, Chief Executive Officer,...

CVM : 6.36 (-1.85%)
CEL-SCI Announces Closing of $10 Million Public Offering

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its offering of 1,111,200 shares of its common...

CVM : 6.36 (-1.85%)
CEL-SCI Announces Pricing of $10 Million Public Offering

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 1,111,200...

CVM : 6.36 (-1.85%)
CEL-SCI Announces Proposed Public Offering

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced that it intends to offer to sell shares of...

CVM : 6.36 (-1.85%)
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

CEL-SCI to sign partnership agreement in Saudi Arabia—Potential for patient access and reimbursement/sale of Multikine in Saudi Arabia within approximately 60...

CVM : 6.36 (-1.85%)
CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

Memorandum of Understanding (MOU) signed with a leading Saudi Arabian pharma company which submitted the Breakthrough Medicine Designation...

CVM : 6.36 (-1.85%)
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

/CNW/ -- Equity Insider News Commentary – Routine medical appointments or cancer screenings—critical for catching the disease in earlier, more treatable...

ONCY : 0.9931 (-0.53%)
ONC : 319.06 (-0.55%)
CVM : 6.36 (-1.85%)
ONC.TO : 1.42 (+2.16%)
ATNM : 1.5100 (+4.14%)
OSTX : 1.81 (-10.84%)
Cel-Sci Stock Slips After Public Offering: Retail's Neutral

The purchase price of each pre-funded Warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.01.

IWC : 163.93 (-1.52%)
VXF : 213.72 (-1.64%)
VTI : 335.99 (-1.14%)
CVM : 6.36 (-1.85%)
Have a Relaxing Holiday Season

Monday U.S. Economic Lookahead Consumer confidence (Dec.) Featured Earnings Limoneira ...

OTLK : 1.98 (-1.00%)
PFX : 43.50 (+4.82%)
LMNR : 14.91 (-0.33%)
CVM : 6.36 (-1.85%)

Business Summary

CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins,...

See More

Key Turning Points

3rd Resistance Point 7.21
2nd Resistance Point 6.98
1st Resistance Point 6.67
Last Price 6.36
1st Support Level 6.13
2nd Support Level 5.90
3rd Support Level 5.59

See More

52-Week High 32.70
Fibonacci 61.8% 20.96
Fibonacci 50% 17.34
Fibonacci 38.2% 13.72
Last Price 6.36
52-Week Low 1.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar